Eli Lilly makes $3bn US investment as demand for weight loss drugs risesProactive Investors • 12/06/24
Billionaire Izzy Englander Is Buying This Obesity Drug Stock That Could Soar Nearly 20%, According to Wall StreetThe Motley Fool • 12/06/24
Lilly announces $3 billion expansion of its recently acquired manufacturing facility in WisconsinPRNewsWire • 12/05/24
The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion MarketInvestors Business Daily • 12/05/24
LLY's Zepbound Outshines NVO's Wegovy in Head-to-Head Obesity StudyZacks Investment Research • 12/05/24
Lilly's Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss SupremacySeeking Alpha • 12/04/24
Rondo Therapeutics Announces Collaboration with Lilly to Develop Novel CD28 Bispecific Antibodies for Solid TumorsBusiness Wire • 12/04/24
Eli Lilly's Zepbound Beats Novo Nordisk's Wegovy In Head-To-Head Weight-Loss TrialInvestors Business Daily • 12/04/24
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trialCNBC • 12/04/24
Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%PRNewsWire • 12/04/24